Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.32
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.32
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$6.32 - $12.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.30K
Market Cap
$30.45M
Enterprise Value-$38.76
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.1
Beta0.67
Next Earnings
Nov 09, 2026EPS Estimate
-3.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume7,208
30 Day Avg. Volume28,298
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.00Price Target Upside391.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-13.75
Revenue Forecast (FY)$9.95M
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology PlatformThe non-PSMA therapeutic and companion-imaging combination could support patient selection and differentiate Kyntra in mCRPC. CD46 expression and a potentially more uniform target may create a durable clinical and commercial niche.
Clinical Pipeline ProgressDefined development milestones provide multiple opportunities for durable value creation over the next several months. Advancement toward pivotal testing can reduce early-stage uncertainty and establish clearer paths to potential registration.
Liquidity And Debt PositionThe stated runway into 2028 and absence of TTM debt give Kyntra time to advance clinical programs without immediate leverage pressure. This supports operational continuity and improves flexibility while milestones are pursued.
Bears Say
Shrinking Revenue And Weak MarginsPersistent revenue contraction and sharply lower gross margin indicate a weak operating base. Without a recovery in recurring revenue or product economics, funding clinical development will remain dependent on cash reserves or external financing.
Cash Burn And Negative EquityOngoing cash consumption reduces financial flexibility even with no debt, and negative equity signals an accumulated deficit and limited capital cushion. Continued development spending could increase reliance on partners or future capital.
Execution And Funding RiskThe registrational path for roxadustat carries material financing and economics uncertainty. A partner may reduce funding needs but dilute returns, while internal development preserves economics but could accelerate cash use and royalty obligations.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio, Inc.’s price range in the past 12 months?
Kyntra Bio, Inc. lowest stock price was $6.32 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio, Inc.’s market cap?
Kyntra Bio, Inc.’s market cap is $30.45M.
When is Kyntra Bio, Inc.’s upcoming earnings report date?
Kyntra Bio, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 78 days.
How were Kyntra Bio, Inc.’s earnings last quarter?
Kyntra Bio, Inc. released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio, Inc. overvalued?
According to Wall Street analysts Kyntra Bio, Inc.’s price is currently Undervalued.
Does Kyntra Bio, Inc. pay dividends?
Kyntra Bio, Inc. does not currently pay dividends.
What is Kyntra Bio, Inc.’s EPS estimate?
Kyntra Bio, Inc.’s EPS estimate is -3.66.
How many shares outstanding does Kyntra Bio, Inc. have?
Kyntra Bio, Inc. has 4,049,124 shares outstanding.
What happened to Kyntra Bio, Inc.’s price movement after its last earnings report?
Kyntra Bio, Inc. reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went up 0.142%.
Which hedge fund is a major shareholder of Kyntra Bio, Inc.?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio, Inc.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$36.00
▲(391.80% Upside)
Technical Analysis
Ownership Overview
3.37% Insiders
22.60% Mutual Funds
10.45% Other Institutional Investors
59.71% Public Companies and
Individual Investors